Two New Studies to Explore Telix Assets in Breast Cancer Theranostics

NEXT STORY
H1 2021: Tecan reports substantial double-digit growth in sales and more than a doubling in net profit – on top of an already strong performance in the prior-year period
PREV STORY
Telix and Merck to Commence Pan-Cancer Clinical Combination Studies
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Basilea announces completion of patient enrolment into first cohort of phase 2 study FIDES-01 with derazantinib in bile duct cancer (iCCA)

author_avatar
NASDAQ Market News

Bavarian Nordic Announces Interim Results for the First Three Months of 2016

COPENHAGEN, Denmark, May 13, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced ...

author_avatar
NASDAQ Market News

Cerecor and Aevi Genomic Medicine Complete Merger

author_avatar
NASDAQ Market News